B. Riley initiates Foghorn Therapeutics at buy with $10 price target, citing promising development of SMARCA2 inhibitors for ...

Foghorn Therapeutics (FHTX) has received a new Buy rating, initiated by B.Riley Financial analyst, Kalpit Patel.Invest with Confidence: Follow ...

We recently published a list of 12 Stocks That Could Split in the Near Future. In this article, we are going to take a look at where Eli Lilly And Co. (NYSE:LLY) stands against other stocks that could ...

Foghorn Therapeutics Inc. (FHTX) has been beaten down lately with too much selling pressure. While the stock has lost 23.1% over the past four weeks, there is light at the end of the tunnel as it ...

Shares of Eli Lilly have been falling in recent months, but that could spell opportunity. Investors appear to be concerned that a new government could impact its growth potential. The business is ...

Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Eli Lilly shares could remain under the microscope on Wednesday after falling sharply ...

SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens, it framed the move as a way ...

Eli Lilly announced preliminary fourth-quarter revenue of roughly $13.5 billion, or $400 million below the low end of its guidance, driven by slower-than-expected US market growth and lower ...

Like many other biopharma companies presenting at this year’s J.P. Morgan Healthcare Conference, Eli Lilly took a chance on Tuesday to share its preliminary sales results for 2024. Unfortunately ...

Ore Huiying / Bloomberg / Getty Images Eli Lilly shares tumbled Tuesday after the drugmaker lowered its revenue forecast for the 2024 fiscal year. The maker of weight-loss drugs Mounjaro and ...

Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes ...